Abstract: Provided are: an oligosaccharide powder having high working properties, the oligosaccharide powder being characterized by containing a dextrin having a dextrose equivalent of 10 to 18 and an oligosaccharide; and a method for manufacturing the same.

Abstract: Provided is a method for using a STAT3 inhibitor which exhibits an excellent antitumor effect. An antitumor agent comprises a quinoline carboxamide derivative of formula (I) below or a salt thereof as an active ingredient, and is administered in combination with an immune checkpoint inhibitor. The antitumor agent is administered before the administration of the immune checkpoint inhibitor.

Abstract: Provided is a method for industrially advantageously synthesizing a production intermediate of a quinolinecarboxamide derivative or a salt thereof. The present invention provides a method for producing a quinolinecarboxylic acid derivative of formula (4) or a salt thereof, including reacting an aniline of the following formula (1), in the presence of boron trifluoride-tetrahydrofuran complex or boron trifluoride-diethyl ether complex, with an aldehyde of formula (2) and subsequently reacting the resulting compound with an ?-keto acid of formula (3), wherein R1, R2, R3 and R4 are the same or different and each represent a hydrogen atom, a halogen atom, a lower alkyl group, or the like, R5 represents a hydrogen atom, a lower alkyl group, or the like, and R6 represents a hydrogen atom, a lower alkyl group, or the like.

Abstract: A proliferation promoting effect on lactic acid bacteria during production and a viability improving effect during storage are obtained by a method for producing a lactic acid bacterium fermentation food product characterized in that when a lactic acid bacterium fermentation food product is produced by inoculating and culturing lactic acid bacteria in a medium containing a milk or a milk product as a main component, a lipase degradation product of an oil or fat is added to the medium containing a milk or a milk product as a main component before culturing lactic acid bacteria, or to a fermented liquid during or after culturing.

Abstract: Provided is a novel Bifidobacterium strain capable of utilizing xylans. Bacteria belonging to the genus Bifidobacterium having a xylanase gene on a genome.

Abstract: Provided is a novel agent for improving sleep quality. An agent for improving sleep quality containing, as an active ingredient, bacterial cells of Lactobacillus casei and/or a treated product thereof.

Abstract: A bacterium belonging to the genus Pseudomonas such as Pseudomonas aeruginosa is specifically and quantitatively detected using a selection medium for a bacterium belonging to the genus Pseudomonas characterized by containing, in a basal medium, at least one third-generation cephalosporin and at least one antibiotic selected from the group consisting of a first-generation cephalosporin and a glycopeptide-based antibiotic and by a method for detecting a bacterium belonging to the genus Pseudomonas and a method for selecting a bacterium belonging to the genus Pseudomonas through use of said selection medium.

Abstract: By a method for producing a culture for obtaining a culture by culturing a lactic acid bacterium and/or a bacterium belonging to the genus Bifidobacterium in a milk peptide-containing medium which is characterized in that a culture temperature is 3° C. or more lower than an optimum culture temperature of the lactic acid bacterium and/or the bacterium belonging to the genus Bifidobacterium, the change in the acidity during the storage of the product is not accelerated, and the bacterial count at the time of the preparation of the product can be maintained at a high level, even when the lactic acid bacterium or the like is cultured in a medium containing a milk peptide added thereto.

Abstract: Provided is a method for improving the production amount of a tri- or higher galactooligosaccharide and the reaction rate by a method for producing a galactooligosaccharide characterized by allowing ?-galactosidase to react with a substrate in the presence of 5 to 60 mM sodium ions and 0.5 to 8 mM magnesium ions.

Abstract: A marker may determine sensitivity to an anti-cancer agent early after the start of treatment with the anti-cancer agent. The anti-cancer agent may include oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker including one or more molecules selected from the group consisting of 2AMAD, 2ABA, 2CYPR, 5OPRO, 6AHXA, ADEN, ASP, BETNC, CARB, CSSG, DOPM, GGLCY, GSSG, HYPT, METSF, N6MDA, NOMTR, PHEP, PRO, and RIB5P.

Abstract: The purpose of the present invention is to provide a heat-shrinking apparatus for shrink labels which is capable of uniformly heat shrinking a shrink label covering a portion or the entirety of an article, and which is capable of completing heat shrinking in a state in which water drops are not deposited on the article and the surface of the shrink label.

Abstract: For providing a method capable of physically and objectively evaluating the consistency and state of a stool, provided is a method for measuring a stool consistency with a texture analyzer provided with a probe, the probe having a shape capable of measuring a consistency of a stool in a liquid form and in a solid form.

Abstract: Provided is a culture product having a mild rose aroma and suitable for imparting the rose aroma to a cosmetic product, a food or a drink, a pharmaceutical product, and the like. A culture product, which is obtained by fermenting a lactic acid bacterium culture product in a medium containing a milk component with Kluyveromyces marxianus, and comprises isoamyl alcohol in an amount of 0.3 to 5 parts by mass with respect to 1 part by mass of phenylethyl acetate.

Abstract: Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drugs selected from the group consisting of an ALK inhibitor, an EGFR inhibitor, a multi kinase inhibitor, a HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor and a BCR-ABL inhibitor, wherein R1, R2, R3, R4, R5 and R6 are the same or different, and each represent a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, COOR7 (wherein R7 represents a substituted or unsubstituted alkyl group), or OR8 (wherein R8 represents a substituted or unsubstituted alkyl group).

Abstract: An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.

Abstract: A method for producing a secreted ?-galactosidase, characterized by integrating a non-secreted ?-galactosidase gene derived from a basidiomycetous yeast into Aspergillus oryzae to produce a secreted ?-galactosidase, and a method for producing a galactooligosaccharide using a ?-galactosidase produced by the method facilitate the production of a galactooligosaccharide.

Abstract: To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.

Abstract: Provided are a compound superior in a cytotoxic action on cancer cells, an action inducing degradation of BET protein in cancer cells, and an inhibitory action on the binding of BET protein and acetylated histone, and useful as an anticancer agent, a BET protein degradation inducer or a BET protein inhibitor.

Abstract: Provided is a novel preventive or therapeutic agent for celiac disease. A preventive or therapeutic agent for celiac disease, comprising at least one bacterium belonging to the genus Bifidobacterium selected from the group consisting of Bifidobacterium breve and Bifidobacterium bifidum and/or a processed bacterial cell thereof as an active ingredient.

Abstract: Provided is a method for producing skim milk powder in which the amount of free fatty acids has been increased without bringing about deterioration of flavor. The method for producing skim milk powder comprises a step of carrying out homogenization treatment under temperature conditions of 30 to 55° C. in a process of producing the skim milk powder from skim milk.